ArticleCureus2025
Cerebellar Hemangioblastoma Resection Complicated by Postoperative Vasogenic Edema in the Setting of Concurrent Immunotherapy Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemangioblastomas are rare, benign vascular tumors of the central nervous system that are often found in the cerebellum, brainstem, or spinal cord. Common clinical symptoms are related to the mass effect, such as headaches, ataxia, and hydrocephalus. While hemangioblastomas frequently present with vasogenic edema, sustained postoperative edema after tumor resection is an unexpected finding. We report a case of cerebellar hemangioblastoma in a 66-year-old male patient with metastatic prostate cancer and progressive headaches, dizziness, and ataxia. Surgical resection was complicated by significant postoperative edema and worsening of symptoms, requiring urgent reoperation. The patient's chemotherapeutic regimen included docetaxel and leuprolide, which have both been reported in cases of vasogenic edema. Chemotherapy drugs induce endothelial cell dysfunction and trigger vascular leakage, resulting in vasogenic edema. Additionally, gonadotropin-releasing hormone (GnRH) agonists such as leuprolide may impair cerebrospinal fluid (CSF) regulation, resulting in increased intracranial pressure and subsequent edema. The combination of immunosuppressive drugs and GnRH agonists in this patient's cancer treatment regimen, along with vascular disruption from the hemangioblastoma itself, may have had a synergistic effect on vasogenic edema development. Our patient's postoperative edema was successfully managed via decompressive laminectomy and placement of a ventriculoperitoneal shunt, with resolution of symptoms seen postoperatively and at the 12-week follow-up. Tumor surgeons should be advised that patients on chemotherapy and immunotherapy agents may be at higher risk of postoperative edema and an associated mass effect on the surrounding structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.